Navigation Links
Reportlinker Adds Top 10 Drug Delivery Technologies (2010 - 2015)
Date:9/28/2010

NEW YORK, Sept. 28 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Top 10 Drug Delivery Technologies (2010 - 2015)

http://www.reportlinker.com/p0304769/Top-10-Drug-Delivery-Technologies-2010---2015.html

Global Top 10 Drug Delivery Technologies Market (2008 – 2015)

The increasing demand for effective delivery of novel biopharmaceuticals is driving the growth of the global top 10 drug delivery technologies market. Further, patent expirations of drugs is also boosting market growth. The global top 10 drug delivery technologies market is expected to grow from $43.8 billion in 2009 to $81.5 billion in 2015, at an estimated CAGR of 11% from 2010 to 2015. The time release technologies market commands the largest share of the overall top 10 drug delivery technologies market owing to immense popularity of once-daily formulations.

Unconventional modes of drug delivery such as pulmonary, nasal and transdermal are gaining a lot of popularity especially in chronic disease conditions such as diabetes, hypertension, CNS and cancer. Nanotechnology advances have led to the development of innovative drug delivery systems.

Scope of the reportThis research report categorizes the global market top 10 drug delivery technologies on the basis of their growth, therapeutic areas, patents registered, and industry focus. The report analyzes geography; forecasting revenues and trends in each of the following submarkets:

  • Time release technologies
  • Targeted delivery
  • Aerosol technology
  • Encapsulation technology
  • Topical formulations
  • Injectables
  • Trandermal patch
  • Implant technology
  • Liposomal drug delivery
  • PEGlyation technology

  • Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 20 company profiles covering all the sub-segments.

    What makes our reports unique?- We provide the longest market segmentation chain in this industry- not many reports provide market breakdown up to level 5.

    - We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.

    - We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.

    - Comprehensive market analysis for the following sectors:

    Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

    Key questions answered- Which are the high-growth segments/cash cows and how is the market segmented in terms of the top 10 drug delivery technologies?

    - What are market estimates and forecasts; which markets are doing well and which are not?

    - Where are the gaps and opportunities; what is driving the market?

    - Which are the key playing fields? Which are the winning edge imperatives?

    - How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

    Powerful Research and analysisThe analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

    TABLE OF CONTENTS EXECUTIVE SUMMARY

    OBJECTIVE

    MARKET SCENARIO

    EMERGING TECHNOLOGIES

    1 INTRODUCTION

    1.1 KEY TAKE-AWAYS

    1.2 REPORT DESCRIPTION

    1.3 MARKETS COVERED

    1.4 STAKEHOLDERS

    1.5 RESEARCH METHODOLOGY

    2 SUMMARY </b

    3 MARKET OVERVIEW

    3.1 ROLE OF DRUG DELIVERY IN DRUG LIFE CYCLE

    3.2 STAKEHOLDERS

    3.3 CHALLENGES

    3.3.1 GOVERNMENT REGULATIONS

    3.3.2 PRICING PRESSURE, REIMBURSEMENT, & THIRD-PARTY DEPENDENCE

    3.3.3 PATENT LITIGATION

    3.4 CONVENIENCE IS THE KEY FOR COMMERCIAL SUCCESS OF FUTURE DRUGS

    3.5 PATENT ANALYSIS

    4 MARKET DYNAMICS

    4.1 DRIVERS

    4.1.1 PATENT EXPIRATION OF DRUGS

    4.1.2 NEED FOR EFFECTIVE DELIVERY OF NOVEL PHARMACEUTICALS & BIOPHARMACEUTICALS

    4.1.3 REDUCE ATTRITION RATES & SPEED DRUG DISCOVERY/DEVELOPMENT PROCESSES

    4.1.4 EXPANDED APPLICATIONS OF UNCONVENTIONAL MODES OF DRUG DELIVERY

    4.1.5 INNOVATIONS IN DRUG DELIVERY TECHNOLOGIES

    4.2 RESTRAINTS

    4.2.1 DRUG FAILURES RAISE CONCERNS OF ROI

    4.2.2 PHARMA COMPANIES DEVELOP IN-HOUSE DRUG DELIVERY CAPABILITIES

    4.2.3 U.S. HEALTHCARE REFORMS

    4.3 OPPORTUNITIES

    4.3.1 HOME-CARE DRUG DELIVERY DEVICES AND SELF-ADMINISTRATION

    4.3.2 NICHE THERAPEUTIC AREAS

    4.3.3 WELLNESS PRODUCTS

    5 TIME RELEASE TECHNOLOGY

    5.1 DRIVERS

    5.1.1 TIME RELEASE FORMULATIONS IN KEY THERAPEUTIC AREAS

    5.1.2 ONCE-A-DAY FORMULATIONS

    5.1.3 COST EFFECTIVE

    5.2 RESTRAINTS

    5.2.1 LIMITED NUMBER OF MATERIALS

    5.2.2 TECHNICAL BARRIERS

    5.3 OPPORTUNITIES

    5.3.1 PARTICULATE AND CHRONOPHARMACOKINETIC SYSTEMS

    5.3.2 MUCOADHESIVE DRUG DELIVERY

    5.4 BIODEGRADABLE POLYMERS

    5.5 MULTIPARTICULATE BEAD SYSTEMS

    5.6 MATRIX SYSTEMS

    5.7 REGULATORY ENVIRONMENT

    5.8 TIMED RELEASE VS IMMEDIATE RELEASE FORMULATIONS

    5.9 INNOVATIONS IN TIME RELEASE TECHNOLOGIES

    5.1 INDUSTRY INSIGHTS

    5.11 WINNING IMPERATIVES

    5.12 COMPETITIVE DEVELOPMENTS

    6 TARGETED DELIVERY

    6.1 DRIVERS & RESTRAINTS

    6.1.1 INCREASED DEMAND FOR TREATMENT OF CANCEROUS TUMORS

    6.1.2 LACK OF TARGETED DRUG DELIVERY TECHNOLOGIES FOR TREATMENT OF BRAIN TUMOR

    6.1.3 HIGH COST OF TARGETED ANTIBODY-BASED CANCER THERAPEUTICS

    6.2 OPPORTUNITY

    6.2.1 NOVEL TARGETED DRUG DELIVERY SYSTEMS

    6.3 TARGETING LIGANDS

    6.4 NON-BIOLOGICAL TARGETING PLATFORMS

    6.5 TYPES OF TARGETED THERAPIES & COMPANY FOCUS

    6.6 IMPACT OF TARGETED DRUG DELIVERY IN CANCER & OTHER CHRONIC CONDITIONS

    6.7 INNOVATIONS

    6.8 INDUSTRY INSIGHTS

    6.9 WINNING IMPERATIVES

    7 ENCAPSULATION TECHNOLOGIES

    7.1 DRIVERS & RESTRAINTS

    7.1.1 ENHANCED BIOAVAILABILITY

    7.1.2 EXTENSIVE USAGE IN TASTE MASKING AND FASTER DISSOLVING PILLS

    7.1.3 ECONOMICALLY FEASIBLE

    7.1.4 RELUCTANCE IN INVESTING IN NOVEL TECHNOLOGIES

    7.2 OPPORTUNITY

    7.2.1 SOPHISTICATED MICROENCAPSULATION SYSTEMS

    7.3 MICROENCAPSULATION

    7.4 NANOENCAPSULATION

    7.5 EVOLUTION OF ENCAPSULATION TECHNOLOGIES

    7.6 APPLICATION OF ENCAPSULATION TECHNOLOGIES IN DIFFERENT MODES OF DRUG DELIVERY

    7.7 INDUSTRY INSIGHTS

    7.8 WINNING IMPERATIVES

    7.9 COMPETITIVE DEVELOPMENTS

    8 TOPICAL FORMULATIONS

    8.1 DRIVERS & RESTRAINTS

    8.1.1 BURN & WOUND TREATMENT

    8.1.2 BYPASSING FIRST PASS EFFECT

    8.1.3 CONVENIENCE FACTOR

    8.1.4 USAGE IN LIMITED THERAPEUTIC AREAS

    8.2 OPPORTUNITY

    8.2.1 TECHNOLOGY ADVANCEMENTS EXPAND APPLICATIONS

    8.3 GEL TECHNOLOGY

    8.4 MICROEMULSIONS

    8.5 BIPHASIC SYSTEM

    8.6 OTHERS

    8.7 INDUSTRY INSIGHTS

    8.8 WINNING IMPERATIVES

    8.9 COMPETITIVE DEVELOPMENTS

    9 AEROSOL TECHNOLOGY

    9.1 DRIVERS & RESTRAINTS

    9.1.1 INCREASE IN ASTHMA & COPD PATIENTS

    9.1.2 TECHNOLOGICAL ADVANCEMENTS IN AEROSOL FORMULATION AND DEVICE DESIGN

    9.1.3 EASE OF USE, SELF-ADMINISTRATION, & PAINLESS DRUG DELIVERY

    9.1.4 FAILURE OF EXUBERA

    9.2 OPPORTUNITY

    9.2.1 APPLICATION IN NON-RESPIRATORY CONDITIONS

    9.3 DRY POWDER INHALERS

    9.4 METERED DOSE INHALERS

    9.5 NEBULIZERS

    9.6 EVOLUTION OF AEROSOL TECHNOLOGY

    9.7 REGULATORY ENVIRONMENT

    9.8 INNOVATIONS IN AEROSOL TECHNOLOGY

    9.9 INDUSTRY INSIGHTS

    9.1 WINNING IMPERATIVES

    9.11 COMPETITIVE DEVELOPMENTS

    10 TRANSDERMAL PATCH TECHNOLOGY

    10.1 DRIVERS

    10.1.1 REDUCED SIDE EFFECTS & BETTER EFFICACY

    10.1.2 CONVENIENT AND LESS PAINFUL

    10.2 RESTRAINTS

    10.2.1 RECALL OF DURAGESIC AND ORTHO EVRA PATCH

    10.2.2 LOW SKIN PERMEABILITY OF DRUGS

    10.3 OPPORTUNITIES

    10.3.1 NEW PRODUCTS

    10.4 ADHESIVES

    10.5 PHYSICAL ENHANCERS

    10.6 CHEMICAL ENHANCERS

    10.7 INDUSTRY INSIGHTS

    10.8 WINNING IMPERATIVES

    10.9 COMPETITIVE DEVELOPMENTS

    11 IMPLANT TECHNOLOGY

    11.1 DRIVERS & RESTRAINTS

    11.1.1 SELECTIVE DRUG DELIVERY & LOW AMOUNT OF ACTIVE DRUG INGREDIENT

    11.1.2 DOSING ADMINISTRATION NOT REQUIRED

    11.1.3 INCONVENIENCE

    11.2 OPPORTUNITY

    11.2.1 TECHNOLOGICAL ADVANCES ENHANCE APPLICATIONS

    11.3 MEMS IMPLANTS

    11.4 POLYMER WAFERS

    11.5 INTRAOCULAR IMPLANTS

    11.6 PUNCTAL PLUGS

    11.7 INDUSTRY INSIGHTS

    11.8 WINNING IMPERATIVES

    12 INJECTABLE DRUG DELIVERY TECHNOLOGY

    12.1 DRIVERS

    12.1.1 FAVORITES FOR DELIVERY OF BIOLOGICAL DRUGS AND GENE THERAPY

    12.1.2 GROWTH IN THE PREFILLED SYRINGES AND AUTOINJECTOR MARKET

    12.2 RESTRAINTS

    12.2.1 INVASIVENESS & FEAR OF INJECTABLES

    12.2.2 SELF-ADMINISTRATION REMAINS AN ISSUE

    12.3 OPPORTUNITY

    12.3.1 MICRONEEDLES & NEEDLELESS SYSTEMS

    12.4 EVOLUTION OF INJECTABLES

    12.5 INJECTABLE DRUGS IN PIPELINE

    12.6 NEEDLESTICK LEGISLATION

    12.7 INDUSTRY INSIGHTS

    12.8 WINNING IMPERATIVES

    12.9 COMPETITIVE DEVELOPMENTS

    13 LIPOSOMAL DRUG DELIVERY

    13.1 DRIVERS & RESTRAINTS

    13.1.1 ENHANCED USAGE IN CANCER

    13.1.2 EASY MANUFACTURING PROCEDURE & COST EFFECTIVENESS

    13.1.3 SIDE EFFECTS

    13.2 OPPORTUNITY

    13.2.1 NANOSCALE LIPOSOME DRUG DELIVERY

    13.3 INDUSTRY INSIGHTS

    13.4 WINNING IMPERATIVES

    13.5 COMPETITIVE DEVELOPMENTS

    14 PEGYLATION TECHNOLOGIES

    14.1 DRIVERS & RESTRAINTS

    14.1.1 BIOLOGICAL DRUGS

    14.1.2 ENHANCED PHARMACOKINETIC PROPERTIES AND REDUCED DOSAGE

    14.1.3 EXPENSIVE MANUFACTURING PROCEDURE

    14.2 OPPORTUNITY

    14.2.1 TECHNOLOGICAL ADVANCES

    14.3 INDUSTRY INSIGHTS

    14.4 WINNING IMPERATIVES

    15 COMPETITIVE LANDSCAPE

    15.1 ANALYSIS OF TOP PLAYERS

    15.1.1 STRATEGY

    15.2 WINNING IMPERATIVES

    15.2.1 ALLIANCES

    15.2.2 POSITIONING OF DRUG DELIVERY TECHNOLOGY EARLY IN DRUG DISCOVERY

    15.2.3 SHIFT FROM PURE DRUG DELIVERY TOWARD SPECIALTY PHARMACEUTICALS

    15.3 STRATEGIC RECOMMENDATION

    16 GEOGRAPHIC ANALYSIS

    16.1 NORTH AMERICA

    16.2 EUROPE

    16.3 ASIA

    16.4 ROW </b

    17 COMPANY PROFILES

    17.1 ALKERMES, INC

    17.1.1 OVERVIEW

    17.1.2 PRIMARY BUSINESS

    17.1.3 STRATEGY

    17.1.4 DEVELOPMENTS

    17.2 ALTEA THERAPEUTICS, INC

    17.2.1 OVERVIEW

    17.2.2 PRIMARY BUSINESS

    17.2.3 STRATEGY

    17.2.4 DEVELOPMENTS

    17.3 AP PHARMA, INC

    17.3.1 OVERVIEW

    17.3.2 PRIMARY BUSINESS

    17.3.3 STRATEGY

    17.3.4 DEVELOPMENTS

    17.4 APPLIED PHARMA, LTD

    17.4.1 OVERVIEW

    17.4.2 PRIMARY BUSINESS

    17.4.3 STRATEGY

    17.4.4 DEVELOPMENTS

    17.5 ARADIGM, INC

    17.5.1 OVERVIEW

    17.5.2 PRIMARY BUSINESS

    17.5.3 STRATEGY

    17.5.4 DEVELOPMENTS

    17.6 BIOJECT, INC

    17.6.1 OVERVIEW

    17.6.2 PRIMARY BUSINESS

    17.6.3 STRATEGY

    17.6.4 DEVELOPMENTS

    17.7 BIOVAIL, INC

    17.7.1 OVERVIEW

    17.7.2 PRIMARY BUSINESS

    17.7.3 STRATEGY

    17.7.4 DEVELOPMENTS

    17.8 ELAN CORP, PLC

    17.8.1 OVERVIEW

    17.8.2 PRIMARY BUSINESS

    17.8.3 STRATEGY

    17.8.4 DEVELOPMENTS

    17.9 ETHYPHARM LTD

    17.9.1 OVERVIEW

    17.9.2 PRIMARY BUSINESS

    17.9.3 STRATEGY

    17.9.4 DEVELOPMENTS

    17.10 EURAND PHARMACEUTICALS, INC

    17.10.1 OVERVIEW

    17.10.2 PRIMARY BUSINESS

    17.10.3 STRATEGY

    17.10.4 DEVELOPMENTS

    17.11 JOHNSON & JOHNSON, LTD

    17.11.1 OVERVIEW

    17.11.2 PRIMARY BUSINESS

    17.11.3 STRATEGY

    17.11.4 DEVELOPMENTS

    17.12 KV PHARMA CORPORATION

    17.12.1 OVERVIEW

    17.12.2 PRIMARY BUSINESS

    17.12.3 STRATEGY

    17.12.4 DEVELOPMENTS

    17.13 NANOPASS TECHNOLOGIES, LTD

    17.13.1 OVERVIEW

    17.13.2 PRIMARY BUSINESS

    17.13.3 STRATEGY

    17.13.4 DEVELOPMENTS

    17.14 NEKTAR THERAPEUTICS, LTD

    17.14.1 OVERVIEW

    17.14.2 PRIMARY BUSINESS

    17.14.3 STRATEGY

    17.14.4 DEVELOPMENTS

    17.15 PENWEST PHARMACEUTICALS, CO.

    17.15.1 OVERVIEW

    17.15.2 PRIMARY BUSINESS

    17.15.3 STRATEGY

    17.15.4 DEVELOPMENTS

    17.16 QLT, INC

    17.16.1 OVERVIEW

    17.16.2 PRIMARY BUSINESS

    17.16.3 STRATEGY

    17.16.4 DEVELOPMENTS

    17.17 SKYE PHARMA, PLC

    17.17.1 OVERVIEW

    17.17.2 PRIMARY BUSINESS

    17.17.3 STRATEGY

    17.17.4 DEVELOPMENTS

    17.18 VECTURA GROUP, PLC

    17.18.1 OVERVIEW

    17.18.2 PRIMARY BUSINESS

    17.18.3 STRATEGY

    17.18.4 DEVELOPMENTS

    17.19 ENDO PHARMACEUTICALS, INC

    17.19.1 OVERVIEW

    17.19.2 PRIMARY BUSINESS

    17.19.3 STRATEGY

    17.19.4 DEVELOPMENTS

    17.20 LABOPHARM, INC

    17.20.1 OVERVIEW

    17.20.2 PRIMARY BUSINESS

    17.20.3 STRATEGY

    17.20.4 DEVELOPMENTS

    17.21 FLAMEL TECHNOLOGIES, INC

    17.21.1 OVERVIEW

    17.21.2 PRIMARY BUSINESS

    17.21.3 STRATEGY

    17.21.4 DEVELOPMENTS

    17.22 DURECT, CORP

    17.22.1 OVERVIEW

    17.22.2 PRIMARY BUSINESS

    17.22.3 STRATEGY

    17.22.4 DEVELOPMENTS

    17.23 3M

    17.23.1 OVERVIEW

    17.23.2 PRIMARY BUSINESS

    17.23.3 STRATEGY

    17.23.4 DEVELOPMENTS

    APPENDIX U.S. PATENTS

    EUROPE PATENTS

    JAPAN PATENTS

    LIST OF TABLES1 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENTS 2008 – 2015 ($MILLION)

    2 DRUGS EXPECTED TO LOSE PATENT RIGHTS (2010 – 2012)

    3 GLOBAL TIME RELEASE TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)

    4 GLOBAL TIME RELEASE TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    5 GLOBAL BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    6 GLOBAL MULTIPARTICULATE BEAD SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    7 GLOBAL MATRIX SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    8 GLOBAL TARGETED DELIVERY TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)

    9 GLOBAL TARGETED DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    10 GLOBAL TARGETING LIGANDS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    11 GLOBAL NON-BIOLOGICAL TARGETING PLATFORMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    12 GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)

    13 GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    14 GLOBAL MICROENCAPSULATION MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    15 GLOBAL NANOENCAPSULATION MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    16 GLOBAL TOPICAL FORMULATIONS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)

    17 GLOBAL TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY 2008 – 2015

    18 GLOBAL GEL TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    19 GLOBAL MICROEMULSIONS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    20 GLOBAL BIPHASIC SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    21 GLOBAL AEROSOL TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)

    22 GLOBAL AEROSOL TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    23 GLOBAL DRY POWDER INHALERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    24 GLOBAL METERED DOSE INHALERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    25 GLOBAL NEBULIZERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    26 GLOBAL TRANSDERMAL PATCH TECHNOLOGY, BY PRODUCTS 2008 – 2015 ($MILLION)

    27 GLOBAL TRANSDERMAL PATCH TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    28 GLOBAL ADHESIVES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    29 GLOBAL PHYSICAL ENHANCERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    30 GLOBAL CHEMICAL ENHANCERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    31 GLOBAL IMPLANT TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015

    32 GLOBAL IMPLANT TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    33 GLOBAL MEMS IMPLANT MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    34 GLOBAL POLYMER WAFERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    35 GLOBAL INTRAOCULAR IMPLANTS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    36 GLOBAL PUNCTAL PLUGS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    37 GLOBAL INJECTABLES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    38 GLOBAL LIPOSOMAL DRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    39 GLOBAL PEGYLATION TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

    40 ELAN'S PIPELINE DRUGS

    41 BIOVAIL'S PIPELINE DRUGS

    42 ALKERMES'S PIPELINE DRUGS

    43 NEKTAR'S PIPELINE DRUGS

    44 SKYE PHARMA'S PIPELINE DRUGS

    45 TOP COMPANIES & THEIR STRATEGIES

    LIST OF FIGURES1 REVENUE ANALYSIS OF THE TOP 10 DRUG DELIVERY TECHNOLOGIES

    2 TOP 10 DRUG DELIVERY TECHNOLOGIES – MARKET SHARE

    3 EVOLUTION OF DRUG DELIVERY TECHNOLOGY INDUSTRY

    4 ROLE OF DRUG DELIVERY TECHNOLOGIES IN A DRUG LIFE CYCLE

    5 DRUG DELIVERY TECHNOLOGIES AS REVENUE DRIVERS

    6 DRUG DELIVERY MARKET STAKEHOLDERS

    7 IMPACT OF MARKET DRIVERS AND RESTRAINTS

    8 COMPARATIVE ANALYSIS OF DRUG DELIVERY TECHNOLOGIES

    9 PATENT ANALYSIS BY GEOGRAPHY

    10 PATENT ANALYSIS BY SEGMENT (2004 – 2009)

    11 PATENT ANALYSIS BY ASSIGNEE (2004 – 2009)

    12 REASONS FOR FAILURE OF DRUGS IN DRUG DISCOVERY/ DEVELOPMENT PROCESS

    13 EVOLUTION OF TIME RELEASE TECHNOLOGIES

    14 TIME RELEASE VS IMMEDIATE RELEASE

    15 TARGETED THERAPY TYPES

    16 EVOLUTION OF ENCAPSULATION TECHNOLOGIES

    17 ENCAPSULATION APPLICATIONS IN DIFFERENT MODES OF DRUG DELIVERY

    18 EVOLUTION OF AEROSOL TECHNOLOGY

    19 EVOLUTION OF INJECTABLES

    20 COMPETITIVE DEVELOPMENTS (2007 – JUNE 2010)

    21 COMPETITIVE DEVELOPMENTS BY SEGMENT (2007 – JUNE 2010)

    22 REVENUE ANALYSIS (2008 – 2009)

    23 R&D EXPENDITURE (2009)

    24 GLOBAL TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET

    25 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – NORTH AMERICA

    26 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – EUROPE

    27 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ASIA

    28 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ROW

    To order this report: Drug Delivery Technology Industry: Top 10 Drug Delivery Technologies (2010 - 2015) Drug Delivery Technology Business News

    More  Market Research Report

    Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
    '/>"/>

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Reportlinker Adds Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets
    2. Reportlinker Adds Johnson & Johnson: PharmaVitae Profile
    3. Reportlinker Adds Bayer Schering Pharma AG: PharmaVitae Profile
    4. Reportlinker Adds Genzyme Corporation: PharmaVitae Profile
    5. Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
    6. Reportlinker Adds Spinal Surgical Devices: Technologies and Global Markets
    7. Reportlinker Adds Actelion Ltd: PharmaVitae Profile
    8. Reportlinker Adds Pfizer Inc.: PharmaVitae Profile
    9. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    10. Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile
    11. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/11/2016)... Fla. , Feb. 11, 2016 PLAD, ... started out 2016 with sales exceeding company targets, are ... have received their trademark from the United States Patent ... Bobby Clark , Chief Executive Officer of PLAD, Inc.  ... of Pennsylvania with two new ...
    (Date:2/11/2016)... Feb. 11, 2016  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the engagement of Lars E. ... Medical Consultant. Dr. Birgerson will provide strategic medical ... operations team to help ensure timely facilitation of ...
    (Date:2/11/2016)... ENGLEWOOD, Colo. , Feb. 11, 2016  Aytu ... on developing treatments for urological and related conditions, announced ... for the second fiscal quarter of 2016 on Tuesday, ... will review recent accomplishments and provide an overview of ... financial results for the quarter ended December 31, 2015. ...
    Breaking Medicine Technology:
    (Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
    (Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most Promising ... team dedication and commitment to the SharePoint ecosystem. A panel of experts and ... goal is to recognize and promote technology entrepreneurship. , The survey was made ...
    (Date:2/11/2016)... , ... February 11, 2016 , ... ... dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and sports ... sensor for resistance cord exercise and therapy, introduces its new microFET Digital Pinch ...
    (Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... coverage results in significantly higher rates of several common cancer screenings, especially among ... in better outcomes and survival rates. , The study,“What Does Medicaid Expansion ...
    (Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified clinical ... of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve their ... series, known as “Mindfulness for Actors and Artists,” has been featured in ...
    Breaking Medicine News(10 mins):